 |
88 Diseases |  |
13 Trials |
|
13 Trials |  |
791 News |  |
| «123456789101112» |
- | Epogen, Procrit (epoetin alfa) / Amgen
Journal: Successful treatment of chronic hepatitis C virus infection in a patient receiving daily peritoneal dialysis. (Pubmed Central) - May 26, 2019
A patient with end-stage renal disease requiring PD was treated successfully for HCV genotype 1a infection with PrOD fixed-dose combination therapy plus ribavirin therapy. The patient achieved an SVR12 despite withdrawal of ribavirin at treatment week 10, with minimal adverse effects reported.
- || Epogen, Procrit (epoetin alfa) / Amgen
The company announcement was interesting to say the least given the results against epogen (Twitter) - May 10, 2019
- ||||||| Evrenzo (roxadustat) / FibroGen
Trial completion: Himalayas: Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants (clinicaltrials.gov) - Apr 19, 2019
P3, N=1043, Completed, Sponsor: FibroGen
The patient achieved an SVR12 despite withdrawal of ribavirin at treatment week 10, with minimal adverse effects reported. Active, not recruiting --> Completed
- ||||||| Evrenzo (roxadustat) / FibroGen
Trial completion: Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis (clinicaltrials.gov) - Apr 19, 2019
P3, N=741, Completed, Sponsor: FibroGen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Epogen, Procrit (epoetin alfa) / Amgen
Clinical: Your thoughts? Re: Epogen - Should epogen dose be calculated on pre treatment hgb or post treatment hgb. If dose is based on pre tx- by the end of treatment when the diluted hgb is within normal range - the patient received too much Epo. ... cont.. (Twitter) - Apr 13, 2019
- | Eprex (epoetin alfa) / J&J, Epogen (epoetin alfa) / Amgen, Venofer (iron sucrose complex) / Daiichi Sankyo, CSL Behring
Trial initiation date, Adverse events: HOPE-Hb: Hemoglobin Optimization to Prevent Transfusion and Adverse Events in Perioperative Patients With Iron Restricted Anemia (clinicaltrials.gov) - Apr 4, 2019
P2, N=74, Not yet recruiting, Sponsor: St. Michael's Hospital, Toronto
Active, not recruiting --> Completed Initiation date: Oct 2018 --> May 2019
- ||| Vafseo (vadadustat) / Akebia Therap, Mitsubishi Tanabe
Enrollment open, Trial primary completion date: Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa (clinicaltrials.gov) - Mar 22, 2019
P2, N=125, Recruiting, Sponsor: Akebia Therapeutics
Initiation date: Oct 2018 --> May 2019 Not yet recruiting --> Recruiting | Trial primary completion date: Aug 2019 --> Feb 2020
- || Epogen (epoetin alfa) / Amgen, NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: OETNA: Optimized Erythropoietin (EPO) Treatment (clinicaltrials.gov) - Feb 22, 2019
P2, N=62, Active, not recruiting, Sponsor: John A Widness
Not yet recruiting --> Recruiting | Trial primary completion date: Aug 2019 --> Feb 2020 Trial completion date: Jun 2018 --> Dec 2019 | Trial primary completion date: Jun 2018 --> Jun 2019
- | Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Trial completion: Darbepoetin Administration to Preterm Infants (clinicaltrials.gov) - Feb 4, 2019
P2, N=102, Completed, Sponsor: University of New Mexico
Trial completion date: Jun 2018 --> Dec 2019 | Trial primary completion date: Jun 2018 --> Jun 2019 Active, not recruiting --> Completed
- | Epogen (epoetin alfa) / Amgen
Trial completion, Trial completion date, Trial primary completion date: Cross Iron (Comparative Randomized Oral Versus Systemic IRON) (clinicaltrials.gov) - Jan 23, 2019
P=N/A, N=100, Completed, Sponsor: University Hospital, Montpellier
Active, not recruiting --> Completed Recruiting --> Completed | Trial completion date: Jun 2016 --> Oct 2016 | Trial primary completion date: Feb 2016 --> Oct 2016
- |||| Vafseo (vadadustat) / Akebia Therap, Mitsubishi Tanabe
New P2 trial: Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa (clinicaltrials.gov) - Jan 9, 2019
P2, N=125, Not yet recruiting, Sponsor: Akebia Therapeutics
- | Epogen (epoetin alfa) / Amgen
Trial primary completion date, Combination therapy: NCI-2009-01173: Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia (clinicaltrials.gov) - Dec 4, 2018
P3, N=252, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | Trial completion date: Jun 2016 --> Oct 2016 | Trial primary completion date: Feb 2016 --> Oct 2016 Trial primary completion date: Nov 2018 --> Feb 2019
- | Evrenzo (roxadustat) / FibroGen
Trial completion: Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis. (clinicaltrials.gov) - Nov 27, 2018
P3, N=2133, Completed, Sponsor: AstraZeneca
Trial primary completion date: Nov 2018 --> Feb 2019 Active, not recruiting --> Completed
- | Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
Enrollment open: COMMANDS: A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Na (clinicaltrials.gov) - Oct 31, 2018
P3, N=300, Recruiting, Sponsor: Celgene
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
New P3 trial: COMMANDS: A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Na (clinicaltrials.gov) - Sep 24, 2018
P3, N=350, Not yet recruiting, Sponsor: Celgene
- | Jesduvroq (daprodustat) / GSK, Kyowa Kirin
Enrollment open: Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD) (clinicaltrials.gov) - Sep 17, 2018
P3, N=402, Recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Eprex (epoetin alfa) / J&J, Epogen (epoetin alfa) / Amgen, Venofer (iron sucrose complex) / Daiichi Sankyo, CSL Behring
Trial initiation date, Adverse events: HOPE-Hb: Hemoglobin Optimization to Prevent Transfusion and Adverse Events in Perioperative Patients With Iron Restricted Anemia (clinicaltrials.gov) - Sep 5, 2018
P2, N=74, Not yet recruiting, Sponsor: St. Michael's Hospital, Toronto
Not yet recruiting --> Recruiting Initiation date: May 2018 --> Oct 2018
- | Epogen (epoetin alfa) / Amgen
Trial completion date, Trial primary completion date: Long Term Effects of Erythropoietin in Patients With Moderate to Severe Traumatic Brain Injury (clinicaltrials.gov) - Aug 22, 2018
P=N/A, N=603, Recruiting, Sponsor: Australian and New Zealand Intensive Care Research Centre
Initiation date: May 2018 --> Oct 2018 Trial completion date: Jun 2018 --> May 2019 | Trial primary completion date: Oct 2017 --> May 2019
- | Epogen (epoetin alfa) / Amgen
Trial primary completion date, Combination therapy: NCI-2009-01173: Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia (clinicaltrials.gov) - Aug 17, 2018
P3, N=252, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2018 --> May 2019 | Trial primary completion date: Oct 2017 --> May 2019 Trial primary completion date: Jul 2018 --> Nov 2018
- ||||||| Evrenzo (roxadustat) / FibroGen
Trial completion: Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis (clinicaltrials.gov) - Aug 7, 2018
P3, N=838, Completed, Sponsor: Astellas Pharma Europe B.V.
Trial primary completion date: Jul 2018 --> Nov 2018 Active, not recruiting --> Completed
- ||||| Evrenzo (roxadustat) / FibroGen
Enrollment closed, Trial completion date, Trial primary completion date: Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis (clinicaltrials.gov) - Jul 18, 2018
P3, N=820, Active, not recruiting, Sponsor: FibroGen
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Mar 2018 --> Sep 2018 | Trial primary completion date: Mar 2018 --> Sep 2018
- ||||| Evrenzo (roxadustat) / FibroGen
Enrollment closed, Trial completion date, Trial primary completion date: Himalayas: Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants (clinicaltrials.gov) - Jul 18, 2018
P3, N=900, Active, not recruiting, Sponsor: FibroGen
Recruiting --> Active, not recruiting | Trial completion date: Mar 2018 --> Sep 2018 | Trial primary completion date: Mar 2018 --> Sep 2018 Recruiting --> Active, not recruiting | Trial completion date: Mar 2018 --> Sep 2018 | Trial primary completion date: Mar 2018 --> Sep 2018
- ||||| Evrenzo (roxadustat) / FibroGen
Enrollment closed: Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis. (clinicaltrials.gov) - Jun 15, 2018
P3, N=2128, Active, not recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting | Trial completion date: Mar 2018 --> Sep 2018 | Trial primary completion date: Mar 2018 --> Sep 2018 Recruiting --> Active, not recruiting
- || Jesduvroq (daprodustat) / GSK, Kyowa Kirin
Trial completion date, Trial primary completion date: Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP) (clinicaltrials.gov) - Jun 6, 2018
P2a, N=62, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Trial completion date: Feb 2019 --> May 2019 | Trial primary completion date: Feb 2019 --> May 2019
- | Eprex (epoetin alfa) / J&J, Epogen (epoetin alfa) / Amgen, Venofer (iron sucrose complex) / Daiichi Sankyo, CSL Behring
New P2 trial, Adverse events: HOPE-Hb: Hemoglobin Optimization to Prevent Transfusion and Adverse Events in Perioperative Patients With Iron Restricted Anemia (clinicaltrials.gov) - May 18, 2018
P2, N=74, Not yet recruiting, Sponsor: St. Michael's Hospital, Toronto
- Vafseo (vadadustat) / Akebia Therap
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents (clinicaltrials.gov) - Apr 25, 2018
P2, N=2, Terminated, Sponsor: Akebia Therapeutics
Trial completion date: Feb 2019 --> May 2019 | Trial primary completion date: Feb 2019 --> May 2019 N=50 --> 2 | Trial completion date: Dec 2018 --> Apr 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2018 --> Mar 2018; Revised study design.
- |||| Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen
Trial completion date, Trial primary completion date: Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis. (clinicaltrials.gov) - Mar 27, 2018
P3, N=2070, Recruiting, Sponsor: AstraZeneca
N=50 --> 2 | Trial completion date: Dec 2018 --> Apr 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2018 --> Mar 2018; Revised study design. Trial completion date: Apr 2018 --> Sep 2018 | Trial primary completion date: Apr 2018 --> Sep 2018
- || Jesduvroq (daprodustat) / GSK, Kyowa Kirin
Trial completion date, Trial primary completion date: Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP) (clinicaltrials.gov) - Mar 16, 2018
P2a, N=62, Recruiting, Sponsor: GlaxoSmithKline
Trial completion date: Apr 2018 --> Sep 2018 | Trial primary completion date: Apr 2018 --> Sep 2018 Trial completion date: Jun 2018 --> Feb 2019 | Trial primary completion date: May 2018 --> Feb 2019
- | Epogen (epoetin alfa) / Amgen
Trial initiation date, Trial primary completion date, Combination therapy: NCI-2009-01173: Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia (clinicaltrials.gov) - Mar 5, 2018
P3, N=252, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2018 --> Feb 2019 | Trial primary completion date: May 2018 --> Feb 2019 Initiation date: May 2006 --> Jan 2009 | Trial primary completion date: Feb 2018 --> Jul 2018
- | Epogen (epoetin alfa) / Amgen
Trial completion, Enrollment change, Trial initiation date, HEOR: Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma (clinicaltrials.gov) - Feb 22, 2018
P=N/A, N=31, Completed, Sponsor: The Cleveland Clinic
Initiation date: May 2006 --> Jan 2009 | Trial primary completion date: Feb 2018 --> Jul 2018 Active, not recruiting --> Completed | N=50 --> 31 | Initiation date: Mar 2005 --> Sep 2003
- ||||| Jesduvroq (daprodustat) / GSK, Kyowa Kirin
Trial initiation date: Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD) (clinicaltrials.gov) - Feb 15, 2018
P3, N=402, Not yet recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed | N=50 --> 31 | Initiation date: Mar 2005 --> Sep 2003 Initiation date: Apr 2018 --> Sep 2018
- | Eprex (epoetin alfa) / J&J, Epogen (epoetin alfa) / Amgen
Enrollment open: EPO-PRETAR: A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS (clinicaltrials.gov) - Feb 5, 2018
P3, N=124, Recruiting, Sponsor: Groupe Francophone des Myelodysplasies
Initiation date: Apr 2018 --> Sep 2018 Not yet recruiting --> Recruiting
- |||||||||| Jesduvroq (daprodustat) / GSK, Kyowa Kirin
New P3 trial: Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD) (clinicaltrials.gov) - Jan 17, 2018
P3, N=402, Not yet recruiting, Sponsor: GlaxoSmithKline
- | Vafseo (vadadustat) / Akebia Therap
Enrollment closed: Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents (clinicaltrials.gov) - Jan 16, 2018
P2, N=50, Active, not recruiting, Sponsor: Akebia Therapeutics
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Epogen (epoetin alfa) / Amgen
New P3 trial, Combination therapy: NCI-2009-01173: Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia (clinicaltrials.gov) - Dec 19, 2017
P3, N=252, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- ||| Epogen (epoetin alfa) / Amgen
Enrollment closed, Trial primary completion date: OETNA: Optimized Erythropoietin (EPO) Treatment (clinicaltrials.gov) - Dec 5, 2017
P2, N=62, Active, not recruiting, Sponsor: University of Iowa
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Jun 2018
- | Epogen (epoetin alfa) / Amgen
Trial primary completion date, Combination therapy: NCI-2009-01173: Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia (clinicaltrials.gov) - Oct 25, 2017
P3, N=252, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Jun 2018 Trial primary completion date: Nov 2008 --> Dec 2017
- | Epogen (epoetin alfa) / Amgen
Trial initiation date, Combination therapy: NCI-2009-01173: Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia (clinicaltrials.gov) - Oct 16, 2017
P3, N=249, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Nov 2008 --> Dec 2017 Initiation date: Jan 2009 --> May 2006 | Trial primary completion date: Dec 2017 --> Nov 2008 | Initiation date: Jan 2009 --> May 2006
- | Epogen (epoetin alfa) / Amgen
Trial completion: Generation of Positive Biological Samples to Epoetin for Doping Control. (clinicaltrials.gov) - Oct 5, 2017
P1, N=2, Completed, Sponsor: Parc de Salut Mar
Initiation date: Jan 2009 --> May 2006 | Trial primary completion date: Dec 2017 --> Nov 2008 | Initiation date: Jan 2009 --> May 2006 Active, not recruiting --> Completed
- |||| Mircera (methoxy polyethylene glycol-epoetin beta) / Roche, CSL Behring
Trial completion: A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs) (clinicaltrials.gov) - Sep 26, 2017
P4, N=2828, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Epogen (epoetin alfa) / Amgen
Combination therapy: NCI-2009-01173: Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia (clinicaltrials.gov) - Sep 25, 2017
P3, N=252, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Sep 2017 --> Dec 2017
- | Vafseo (vadadustat) / Akebia Therap
Enrollment change: Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents (clinicaltrials.gov) - Sep 14, 2017
P2, N=50, Recruiting, Sponsor: Akebia Therapeutics
Trial primary completion date: Sep 2017 --> Dec 2017 N=78 --> 50
- | Epogen (epoetin alfa) / Amgen
Enrollment change, Trial termination, Trial primary completion date, Surgery: EPOgen and Restrictive Transfusions in Patients Undergoing Cardiac Surgery (EPORT) (clinicaltrials.gov) - Sep 14, 2017
P1/2, N=4, Terminated, Sponsor: Johns Hopkins University
N=78 --> 50 N=200 --> 4 | Recruiting --> Terminated | Trial primary completion date: May 2017 --> Jun 2016; Loss of funding
- ||||||| Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen
Trial completion: FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease (clinicaltrials.gov) - Aug 24, 2017
P3, N=305, Completed, Sponsor: FibroGen
N=200 --> 4 | Recruiting --> Terminated | Trial primary completion date: May 2017 --> Jun 2016; Loss of funding Active, not recruiting --> Completed
- |||| Jesduvroq (daprodustat) / GSK, Kyowa Kirin
Enrollment open: Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP) (clinicaltrials.gov) - Aug 22, 2017
P2a, N=62, Recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Epogen (epoetin alfa) / Amgen
Enrollment open, Trial initiation date: Long Term Effects of Erythropoietin in Patients With Moderate to Severe Traumatic Brain Injury (clinicaltrials.gov) - Aug 22, 2017
P=N/A, N=603, Recruiting, Sponsor: Australian and New Zealand Intensive Care Research Centre
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Mar 2017 --> Aug 2017
- Farydak (panobinostat) / Secura Bio
Phase classification, Trial termination, Combination therapy: GEPARD: LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - Aug 11, 2017
P2, N=34, Terminated, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting | Initiation date: Mar 2017 --> Aug 2017 Phase classification: P4 --> P2 | Completed --> Terminated; The study was terminated due to lack of efficacy of single agent LBH589 in the 4 month open label core phase and due to enrollment difficulties.
- | Epogen (epoetin alfa) / Amgen
Trial primary completion date: Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia (clinicaltrials.gov) - Aug 9, 2017
P3, N=114, Completed, Sponsor: Gynecologic Oncology Group
Phase classification: P4 --> P2 | Completed --> Terminated; The study was terminated due to lack of efficacy of single agent LBH589 in the 4 month open label core phase and due to enrollment difficulties. Trial primary completion date: Jan 2010 --> May 2004
- | Epogen (epoetin alfa) / Amgen
Trial completion: Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia (clinicaltrials.gov) - Aug 8, 2017
P3, N=114, Completed, Sponsor: Gynecologic Oncology Group
Trial primary completion date: Jan 2010 --> May 2004 Active, not recruiting --> Completed
- | Eprex (epoetin alfa) / J&J, Epogen (epoetin alfa) / Amgen
New P3 trial: EPO-PRETAR: A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS (clinicaltrials.gov) - Jul 21, 2017
P3, N=124, Not yet recruiting, Sponsor: Groupe Francophone des Myelodysplasies